Case-specific hospital estimate

Autologous Stem Cell Transplant for Multiple Myeloma Cost in India

Understand what shapes the quotation and request a current written hospital estimate based on the patient’s medical records—not an unsupported website price.

Request current estimate Understand the procedure →

HSCT and BMT safeguard

Haematopoietic stem-cell transplantation requires specialist programme review.

Autologous and allogeneic HSCT are distinct from solid-organ transplantation. Organ-allocation and deceased-donor waiting-list language does not apply to these pages.

Use an appropriate haematology transplant programme

The treating programme must confirm the indication, patient fitness, cell source, conditioning plan, laboratory and infection-control pathway, consent and follow-up requirements.

For allogeneic HSCT, donor suitability requires independent medical assessment, HLA and compatibility work-up, infection screening, voluntary informed consent and a safe collection plan.
For autologous HSCT, the patient’s own cells are mobilised, collected, processed, stored and reinfused; donor relationship and organ-allocation processes are not relevant.
Cell identity, collection, processing, storage, transport, traceability and release should follow the treating programme’s quality and safety procedures.
Established HSCT for recognised indications must not be confused with unproven “stem-cell therapy.” Investigational use requires the applicable ethics, clinical-trial and regulatory review.
Cell or stem-cell-derived products that fall within India’s new-drug framework may require CDSCO permissions under the New Drugs and Clinical Trials Rules; the treating institution must determine what applies to the proposed product or protocol.
No enquiry, estimate or travel arrangement confirms candidacy, donor suitability, engraftment or outcome.

ICMR National Guidelines for Hematopoietic Cell Transplantation ↗CDSCO New Drugs and Clinical Trials framework ↗

Patient advocacy, not price control

Inmedism® may request and negotiate hospital estimates on a patient’s behalf. Hospitals independently set their prices and decide whether to offer any concession. Inmedism® cannot guarantee a particular quotation, discount or final treatment cost.

Published hospital starting referenceUSD 15,000 onwards

Max Healthcare International currently publishes this starting benchmark for the named treatment. It is that provider’s reference—not an InMedism price, nationwide average, guaranteed package or final quotation.

How to interpret “onwards”

A starting point is not a price range.

The reference may assume a defined transplant type, cell source and uncomplicated engraftment course
Donor search, HLA testing, collection/processing, isolation duration, blood products, high-cost medicines and readmission may be separate
Another hospital may quote a lower or higher amount
Currency conversion and provider pricing may change without notice

Source checked 25 August 2026. Always request a fresh written hospital estimate.

Why the cost varies

No single figure fits every Autologous Stem Cell Transplant for Multiple Myeloma case.

Autologous stem-cell transplantation for multiple myeloma collects the patient’s own blood-forming cells, gives high-dose therapy and then returns the stored cells to restore marrow function. It is commonly part of a broader myeloma plan rather than a stand-alone cure.

✓Mobilisation, apheresis, cell processing and storage
✓Conditioning and transplant admission
✓Blood products, infection management and supportive medicines
✓Post-transplant myeloma monitoring and maintenance treatment
✓Hospital, treating team, room category and city
✓Complications or changes required after examination

Ask what is included

Possible inclusions

Pre-transplant assessment listed in the estimate
Conditioning treatment and stem-cell infusion
Defined isolation-room stay
Routine blood-count and infection monitoring during admission
Standard transfusion and supportive-care allowance where specified
Donor collection or cryopreservation only when expressly included

Clarify before accepting

Possible additional costs

Donor search, HLA typing and cell procurement not stated in the package
Extended isolation, ICU care or delayed engraftment
Additional blood products, antimicrobials or high-cost medicines
Treatment of graft-versus-host disease, infection or organ complications
Cell storage, molecular monitoring and post-discharge medicines
Readmission and longer-term specialist follow-up

Estimate workflow

How Inmedism® coordinates a quotation.

01
Prepare the case
Share current records through the approved secure route.
02
Identify suitable providers
Route the case according to specialty and clinical need.
03
Request clinical scope
The hospital reviews the likely treatment and stay.
04
Negotiate & clarify the hospital estimate
With the patient’s authorization, Inmedism® may discuss the quotation with the hospital on the patient’s behalf, seek clarification of its scope and request consideration of any available concession or revised estimate. Any revision remains entirely at the hospital’s discretion.
05
Compare in writing
Review inclusions, exclusions, validity and payment route.

Before accepting

Questions for the hospital estimate

Which HSCT type, indication, donor or cell source and conditioning protocol does the quotation assume?
Are HLA testing, donor search, cell collection, processing, storage and transport included where applicable?
Which isolation stay, blood products, antimicrobial medicines and monitoring allowances are included?
How are delayed engraftment, infection, graft-versus-host disease and readmission charged?
How long is the quotation valid and what are the provider’s payment instructions?
Does the estimate include conditioning, stem-cell infusion and the defined isolation stay?
Are donor search, HLA testing, cell collection and cryopreservation included where applicable?
What allowance is included for blood products, antimicrobial medicines and supportive care?
How are delayed engraftment, infection or graft-versus-host disease charged?

Important financial boundary

Hospital treatment payment goes directly to the provider.

InMedism facilitates communication and estimate negotiation but does not receive the hospital’s treatment payment through this website.

InMedism coordination fee

InMedism® charges a patient-coordination fee. The applicable service or coordination charge is disclosed separately before the patient agrees to it and is not part of the hospital’s treatment invoice.

Travel and non-clinical services

Travel, visa, accommodation, airport transfer, local transport, meals, interpretation and similar costs are separate unless expressly included in a written quotation. Applicable third-party costs and payment instructions are disclosed separately before the patient confirms those services.

Request estimate coordination

Build a comparable estimate

Separate the clinical, provider and travel budgets.

Clinical scope

Disease status, transplant type, donor and HLA pathway, conditioning, cell collection/processing, engraftment and infection risk.

Provider episode

Pre-transplant assessment, conditioning, cell infusion, protected isolation, laboratory monitoring, transfusion/supportive-care allowances and discharge planning.

Medical travel

Visa, flights, local stay before and after the provider visit, meals, attendant costs, transport, interpretation and an emergency reserve.

Comparison rule

Compare transplant type, cell source, donor/HLA scope, conditioning, processing, isolation allowance, supportive medicines and follow-up.

Relevant doctors

Specialists related to Autologous Stem Cell Transplant for Multiple Myeloma

Explore specialists whose published clinical focus relates to this treatment. Final selection depends on medical-record review, current hospital association and appointment availability.

Search all doctors →